Budesonide/procaterol

Drug Profile

Budesonide/procaterol

Alternative Names: Procaterol/budesonide; SYN-006; Synbitide HFA MDI

Latest Information Update: 24 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intech Biopharm
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Hydroxyquinolines; Pregnenediones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Asthma

Most Recent Events

  • 24 Mar 2017 Budesonide/procaterol is still at phase II development stage for Asthma in Taiwan (Inhalation)
  • 08 Sep 2016 Intech Biopharm has patent protection for Budesonide/procaterol in USA, Canada, Australia, New Zealand, South Korea and Hong Kong (Intech Biopharm website, September 2016)
  • 08 Sep 2016 Intech Biopharm plans phase III trials for Asthma in countries worldwide (Intech Biopharm pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top